I期肺癌经胸肺活检后胸膜复发:系统综述与个体患者水平荟萃分析
该系统综述与个体患者水平荟萃分析纳入6项研究的2394例I期肺癌患者数据,评估经胸肺活检后胸膜复发风险。结果显示经胸活检与同侧胸膜复发风险升高相关(单纯性sHR 2.58,合并其他转移sHR 1.99),且<55岁患者复发时间缩短、肺癌特异性生存和总生存均更差。
要点
- 经胸肺活检与I期肺癌同侧胸膜复发风险升高相关
- <55岁患者经胸活检后复发和生存结局更差
- 需权衡术前经胸活检的获益与胸膜复发风险
核心结论
- 术前经胸肺活检与I期肺癌胸膜复发增加相关,并降低<55岁患者生存。
研究设计与样本
- 系统检索OVID-MEDLINE、Embase和Cochrane系统综述数据库至2018年10月,纳入10项合格研究中的6项,分析2394例个体患者数据。
主要发现
- 与其他诊断方式相比,经胸活检与同侧胸膜复发风险升高相关,单纯性复发sHR 2.58(95%CI 1.15-5.78),合并其他转移sHR 1.99(95%CI 1.14-3.48)。
- <55岁患者中,经胸活检与复发时间缩短(sHR 2.01,95%CI 1.11-3.64)、肺癌特异性生存下降(sHR 2.53,95%CI 1.06-6.05)和总生存下降(HR 2.08,95%CI 1.12-3.87)相关。
- 其他年龄组未观察到上述关联。
临床怎么用
- 对I期肺癌患者选择术前诊断路径时,应告知经胸活检可能增加胸膜复发风险。
- 对<55岁患者,需更谨慎权衡经胸活检的必要性。
局限性
- 仅纳入10项合格研究中的6项,存在选择偏倚可能。
- 为观察性研究的个体患者数据荟萃分析,无法完全排除混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Conflicting results exist regarding whether preoperative transthoracic biopsy increases the risk of pleural recurrence in early lung cancer. We conducted a systematic, patient-level meta-analysis to evaluate the risk of pleural recurrence in stage I lung cancer after percutaneous transthoracic lung biopsy. METHODS: A systematic search of OVID-MEDLINE, Embase and the Cochrane Database of Systematic Reviews was performed through October 2018. Eligible studies were original articles on the risk of pleural recurrence in stage I lung cancer after transthoracic biopsy. We contacted the corresponding authors of eligible studies to obtain individual patient-level data. We used the Fine-Gray model for time to recurrence and lung cancer-specific survival and a Cox proportional hazards model for overall survival. RESULTS: We analysed 2394 individual patient data from 6 out of 10 eligible studies. Compared with other diagnostic procedures, transthoracic biopsy was associated with a higher risk for ipsilateral pleural recurrence, which manifested solely (subdistribution HR (sHR), 2.58; 95% CI 1.15 to 5.78) and concomitantly with other metastases (sHR 1.99; 95% CI 1.14 to 3.48). In the analysis of secondary outcomes considering a significant interaction between diagnostic procedures and age groups, reductions of time to recurrence (sHR, 2.01; 95% CI 1.11 to 3.64), lung cancer-specific survival (sHR 2.53; 95% CI 1.06 to 6.05) and overall survival (HR 2.08; 95% CI 1.12 to 3.87) were observed in patients younger than 55 years, whereas such associations were not observed in other age groups. DISCUSSION: Preoperative transthoracic lung biopsy was associated with increased pleural recurrence in stage I lung cancer and reduced survival in patients younger than 55 years.
引用
- Hong H, Hahn S, Matsuguma H, et al. Pleural recurrence after transthoracic needle lung biopsy in stage I lung cancer: a systematic review and individual patient-level meta-analysis. Thorax. 2021. PMID: 33723018. doi:10.1136/thoraxjnl-2020-216492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。